Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 15/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 15/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 15/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 15/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 15/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917480 | 1.00 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL915995 | 0.94 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL915994 | 0.94 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12904566 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917342 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917341 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13236906 | 0.84 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13264898 | 0.82 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7939810 | 0.82 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2217668 | 0.81 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.